Ovarian Cancer Drugs Market
Ovarian Cancer Drugs Market - Global Industry Assessment & Forecast
#
Pages:
248
2023
Apr - 2024
VMR-2462
Segments Covered
By
Therapeutic Class PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors
-
By
Treatment Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, Other Treatments
-
By
End User Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 3.7 Billion |
 Revenue 2032:
|
USD 6.67 Billion |
 Revenue CAGR
(2024 - 2032): |
6.8% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2018 to 2022 |
| 3. | Forecast Data | 2024 to 2032 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
Vantage Market
Research | 20-May-2024
FAQ
Frequently Asked Question
What is the global demand for Ovarian Cancer Drugs in terms of revenue?
-
The global Ovarian Cancer Drugs valued at USD 3.7 Billion in 2023 and is expected to reach USD 6.67 Billion in 2032 growing at a CAGR of 6.8%.
Which are the prominent players in the market?
-
The prominent players in the market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (UK), Immunogen Inc. (U.S.), Astrazeneca (UK), Merck KGaA (Germany), Oasmia Pharmaceutical AB (Sweden), Clovis Oncology Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Aravive Biologics (U.S.), Allarity Therapeutics (U.S.).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.8% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Ovarian Cancer Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Ovarian Cancer Drugs in 2023.
